Shree Ganesh Biotech India Ltd

Shree Ganesh Biotech India Ltd has reported a flat financial performance for the quarter ended December 2025, signalling a pause in its previously negative trend. Despite a modest improvement in profitability over the nine-month period, the company continues to face operational challenges, particularly in debtor management and revenue growth, which have weighed on investor sentiment and share price performance.

Shree Ganesh Biotech India Ltd. reported a net profit of just ₹0.01 crores for Q2 FY26, representing a staggering decline of 96.97% quarter-on-quarter and 96.88% year-on-year. The micro-cap pharmaceutical company, with a market capitalisation of ₹26.00 crores, continues to struggle with severe revenue contraction and mounting operational challenges. The stock has plunged 34.04% over the past year, closing at ₹0.62 on January 29, 2026, trading 46.09% below its 52-week high of ₹1.15.

Shree Ganesh Biotech India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 08 Aug 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed below represent the company’s current position as of 26 December 2025, providing investors with the latest insights into its performance and prospects.

Shree Ganesh Bio, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market evaluation metrics. This shift reflects ongoing challenges in the company’s financial performance, valuation concerns, and technical indicators, underscoring the difficulties faced by the firm in the current market environment.

Shares of Shree Ganesh Biotech India have reached a new 52-week low of Rs.0.58, marking a significant decline in the stock’s valuation amid a challenging year for the company within the Pharmaceuticals & Biotechnology sector.

Shree Ganesh Biotech India has reached a new 52-week low of Rs.0.58, marking a significant decline in its stock price amid subdued financial performance and challenging market conditions within the Pharmaceuticals & Biotechnology sector.

Shree Ganesh Biotech India has reached a new 52-week low of Rs.0.58, marking a significant decline in its stock price amid broader market gains. The stock's performance contrasts sharply with the positive momentum seen in the Sensex and the Pharmaceuticals & Biotechnology sector.

Shree Ganesh Biotech India has reached a new 52-week low, closing at Rs.0.58 today, marking a significant decline in its stock price amid a challenging year for the company within the Pharmaceuticals & Biotechnology sector.

Shree Ganesh Biotech India has reached a new all-time low price of Rs.0.58, marking a significant milestone in its ongoing decline. The stock's performance continues to lag behind both its sector and the broader market, reflecting persistent pressures within the Pharmaceuticals & Biotechnology industry.

Shree Ganesh Biotech India has reached a new 52-week low, with its share price touching Rs.0.61 today. This significant price level marks a continuation of the stock’s subdued performance over the past year, contrasting with broader market gains.

Shree Ganesh Biotech India has reached a new 52-week low, with its share price touching Rs.0.61 today. This marks a significant decline from its 52-week high of Rs.1.19, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector despite a broadly positive market environment.

Shree Ganesh Biotech India has reached a new all-time low price of ₹0.62, marking a significant milestone in its ongoing decline. The stock’s performance over multiple time frames reveals a persistent downward trajectory, contrasting sharply with broader market gains.

Shree Ganesh Biotech India has reached a new all-time low price of Rs.0.62, marking a significant milestone in its extended period of decline. The stock's performance over multiple time frames reflects persistent challenges within the Pharmaceuticals & Biotechnology sector, contrasting sharply with broader market trends.

Shares of Shree Ganesh Biotech India have reached an all-time low, reflecting a sustained period of subdued performance within the Pharmaceuticals & Biotechnology sector. The stock’s recent price movements and financial indicators highlight the severity of the company’s current position in the market.

Shares of Shree Ganesh Biotech India have declined to a fresh 52-week low of Rs.0.62, marking a significant price level for the pharmaceutical and biotechnology company amid a challenging market environment.

Shree Ganesh Biotech India’s stock reached a new 52-week low of Rs.0.62 today, marking a significant decline amid broader market gains. The stock’s performance contrasts sharply with sector and benchmark indices, reflecting ongoing pressures within the company’s financial and operational metrics.

Shree Ganesh Biotech India has reached a new 52-week low, with its share price touching Rs.0.62 today. This marks a significant decline from its 52-week high of Rs.1.19, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector and the company’s financial performance over the past year.